ÂÜÀòÂÒÂ×

Michael has more than 25 years of operations, IP, legal and transactional experience in the biotech industry and government. Michael has significant prior experience with oncolytic and HSV gene therapy having previously founded and led Nurel Therapeutics until its sale to Diamyd (Stockholm) and Catherex until its sale to Amgen in 2015. He has previously also held positions as a biotech transactional attorney at Cooley Godward, the Federal Trade Commission, and the National Cancer Institute.